Skip to main content

Table 1 Primary diseases leading to anti-TNFα treatment implementation; number (%) of patients in all cases

From: Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study

Primary disease Patients (n = 221) Treatments (n = 261)
Juvenile idiopathic arthritis 163 (73.6) 195 (74.7)
 Polyarticular JIA, positive RF 6 (2.7) 7 (3.8)
 Polyarticular JIA, negative RF 40 (18.1) 48 (18.4)
 Oligoarticular JIA 70 (31.7) 88 (33.7)
 Enthesitis-related arthritis 24 (10.9) 24 (9.2)
 Psoriasic arthritis 11 (5.0) 13 (5.0)
 Undifferentiated disease 12 (5.4) 15 (5.7)
Blau syndrome 1 (0.5) 2 (0.8)
Tumor necrosis factor associated periodic syndrome 1 (0.5) 1 (0.4)
PAPA syndrome 1 (0.5) 1 (0.4)
Chronic plantar fascitis 1 (0.5) 1 (0.4)
Inflammatory bowel disease
 Crohn’s disease 36 (16.3) 39 (14.9)
 Ulcerative colitis 10 (4.5) 11 (4.2)
Inflammatory diseases of the eye
 Uveitis 7 (3.2) 10 (3.8)
Pars planitis 1 (0.5) 1 (0.4)
  1. JIA juvenile idiopathic arthritis, PAPA pyogenic arthritis, pyoderma gangrenosum and acne, RF rheumatoid factor